Comparing Immediate Versus Delayed Use of Febuxostat for Treating Gout Attacks A Phase 3 Study on Starting Hypouricemic Treatment Right Away or After 6 Weeks

What this Trial Is About

Gout is a common inflammatory condition caused by high levels of uric acid leading to painful joint attacks and potentially chronic joint damage, kidney failure, and cardiovascular problems. This trial investigates whether starting febuxostat, a urate-lowering medication, immediately after an acute gout attack is as safe and effective as the current practice of delaying treatment by six weeks. The study aims to better understand if early treatment can prevent worsening of gout and its complications without increasing early relapses. Participants are randomly assigned to one of two groups one begins febuxostat treatment immediately at 80 mg daily for 12 weeks, and the other starts febuxostat only after a six-week delay. The study includes an initial 6-week comparison period, followed by an extension phase where all participants receive febuxostat, and a final evaluation at six months to assess ongoing treatment effects. Febuxostat is chosen for its potency and suitability for patients with moderate kidney issues. Throughout the study, participants will report daily gout symptoms and pain levels using a diary and visual scales. Physical and joint examinations, blood tests to monitor uric acid and inflammation, and assessments of physical function will occur at 2, 6, 12, and 26 weeks. Researchers will track the number of days with gout attacks, treatment tolerance, and overall patient well-being to compare early versus delayed febuxostat use. The study is conducted with blinded evaluators to ensure unbiased results.

Immediate Prescription of a Hypouricemic Treatment, Febuxostat, Compared to Its Delayed Administration